• ANI Pharmaceuticals recently launched Pimozide Tablets 1 mg and 2 mg in the U.S., a generic version of Orap, entering a market with approximately US$3.10 million in annual sales based on February 2026 IQVIA data.
• Coming alongside the launch of Carbamazepine Extended Release Capsules, these additions expand ANI’s generic portfolio and could modestly broaden its revenue base in complex therapies.
• Next, we’ll examine how these new generic launches, particularly Pimozide’s entry into a niche market, may influence ANI Pharmaceuticals’ investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

ANI Pharmaceuticals Investment Narrative Recap

To own ANI Pharmaceuticals, you need to be comfortable with a story centered on expanding higher value rare disease and complex generic franchises while managing payer and pricing pressure, especially around Cortrophin Gel and key first to market generics. The Pimozide launch is small in revenue terms and does not materially change the near term focus on execution in Cortrophin Gel and on how quickly generic margins normalize as exclusivity wanes.

The most directly relevant recent announcement is ANI’s plan to report first quarter 2026 results on May 8, 2026. That update will help frame how much these new generics, including Pimozide and Carbamazepine Extended Release, are contributing relative to expectations, and how they fit into management’s reaffirmed 2026 revenue guidance of US$1,055 million to US$1,115 million and the evolving balance between rare disease and generics.

But against this constructive story, investors should also be aware that payer pushback on high cost therapies like Cortrophin Gel could...

ANI Pharmaceuticals’ narrative projects $1.3 billion revenue and $191.7 million earnings by 2029.

Uncover how ANI Pharmaceuticals' forecasts yield a $110.62 fair value, a 41% upside to its current price.

Exploring Other Perspectives

While consensus leans on multiyear Cortrophin Gel growth, the more cautious analysts see rising payer pressure as a central risk, even as they still project about US$1.2 billion in 2029 revenue and US$204 million in earnings, reminding you that views can differ widely and may shift again as launches like Pimozide and Carbamazepine feed into fresh forecasts.

Explore 7 other fair value estimates on ANI Pharmaceuticals - why the stock might be worth just $90.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ANI Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free ANI Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ANI Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 54 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.